| Name | Title | Contact Details |
|---|
Munchkin is on a mission to be the “World`s Most Loved Baby Lifestyle Brand” through ingenuity, love, and innovation. Founded in 1990 in Los Angeles, California, by CEO Steve Dunn, Munchkin is the leading global baby and toddler consumer products company that develops innovative, modern, and credible products. Munchkin has grown to seven offices worldwide and sells its products in the US, Europe, China, Latin America and Munchkin products are sold in more than 45 countries around the world. A global leader in children`s feeding & care products, Munchkin has 320+ patents to-date and has earned more than 270 design and product awards. We are passionate, creative, and believe in only making the best products, and we`re looking for team members who think big, move fast, work smart, and have a desire to do things better. We pride ourselves in hiring great people with the talent it takes to keep up with our growth. We invite you to explore the “About” page on our website and help achieve our mission to be the most loved global baby lifestyle brand in the world!
Vulcan Pipe and Steel Coatings is a Bessemer, AL-based company in the Manufacturing sector.
Dmp Corp is a Rock Hill, SC-based company in the Manufacturing sector.
Cygnet Stamping & Fabricating is a Glendale, CA-based company in the Manufacturing sector.
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its flagship product, CytoSorb®, is approved in the European Union, distributed in 75 countries worldwide, and has accumulated more than 212,000 human treatments to date, to reduce "cytokine storm" and other toxins that can cause organ failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, has received two U.S. FDA Breakthrough Device Designations to remove two separate blood thinners during cardiothoracic surgery, including ticagrelor and the direct oral anticoagulants (DOAC) apixaban and rivaroxaban, and is undergoing pivotal clinical studies.